Decreased Lysophospholipase and Increased Phospholipase A&lt;sub&gt;2 &lt;/sub&gt;Activity in Heal Mucosa from Patients with Crohn’s Disease

Self Cite

The activity of phospholipase A₂ (EC 3.1.1.4) in endoscopic biopsy specimens of intestinal mucosa was compared in patients with Crohn’s disease and controls without inflammatory bowel disease. In postresection Crohn patients there was significantly enhanced phospholipase A₂ activity proximal to the anastomosis in the neoterminal ileum, whether or not the mucosa was inflamed at the time of biopsy. Highly elevated ileal phospholipase A₂ activity had a predictive value for symptomatic relapse within 1 year after resection. Patients with concomitant Crohn’s colitis, in whom the risk of ileal recurrence is particularly high, had greater ileal phospholipase A₂ activity than noncolitis Crohn patients. Association thus was demonstrated between activity of phospholipase A₂ in ileal mucosa and proneness to ileal inflammation in Crohn’s disease.

mentioning

confidence: 63%

Increased Phospholipase A2 Activity of Heal Mucosa in Crohn’s Disease

Olaison¹,

Sjödahl²,

Tagesson³

1988

Self Cite

“…We previously reported increased permeability of inflamed ileal seg ments in Crohn's disease [1], We also found enhanced phospholipase A2 activity in the ileal mucosa of patients with previous resec tion for Crohn's ileitis whether or not there was recurrent inflammation [2,3]. The pos sibility of a relationship between inflamma tion, phospholipase A2 activity and perme ability of intestinal mucosa in inflammatory bowel disease, though intriguing, does not seem to have been hitherto investigated.…”

mentioning

confidence: 76%

Increase in Permeability and Phospholipase A2 Activity of Colonic Mucosa in Crohn’s Colitis

Olaison¹,

Leandersson

Sjödahl³

et al. 1989

Patients with Crohn’s colitis were investigated regarding the relationship between intestinal inflammation, mucosal activity of phospholipase A₂ and intestinal permeability to different-sized polyethylene glycols (PEG). Mucosal specimens for phospholipase A₂ were obtained at colonoscopy and PEG (590–942 daltons) were deposited in the descending colon. Colonic absorption was measured as urinary output of deposited PEG. Colonic absorption of PEG was higher in these patients, even when the colitis was in remission at colonoscopy, than in ileal Crohn’s disease or control patients. Mucosal phospholipase A₂ activity was increased in active colitis, but in the patients with endoscopic remission it was at the same level as in the controls or in the patients with ileal Crohn’s disease. The observations suggest that increased intestinal permeability may be a primary factor in activation of mucosal phospholipase A₂ activity and in intestinal inflammation.

“…On the other hand, it remains entirely unclear whether decreased en zyme activity underlies or is due to the disease process. Moreover, there is no reason to believe that the decrease in PAF acetylhydrolase is specific, because previous studies have shown that in the intestinal mucosa of patients with Crohn's disease the activities of a number of different enzymes are lower [36,38]. In addition, the activity of PAF acetylhydrolase in intestinal mucosa during other inflam matory disorders of the bowel remains to be investigated in order to test whether the changes are disease specific.…”

Section: Discussionmentioning

confidence: 99%

Platelet-Activating Factor Acetylhydrolase Activity in Intestinal Mucosa and Plasma of Patients with Crohn’s Disease

Kald

Smedh²,

Olaison³

et al. 1996

Self Cite

The activity of platelet-activating factor (PAF) acetylhydrolase in biopsy specimens of intestinal mucosa was compared in patients with Crohn’s disease (n = 11) and controls (n = 6). In addition, PAF acetylhydrolase activity was determined in the plasma of Crohn patients (n = 30) and healthy subjects (n = 35). The activity of PAF acetylhydrolase in mucosal samples from the distal ileum was significantly lower in Crohn patients than in control patients (p < 0.02), whereas there was no difference in PAF acetylhydrolase activity of colonic or jejunal samples between Crohn patients and controls. The PAF acetylhydrolase activity in the plasma of Crohn patients was significantly decreased as compared to healthy subjects. Crohn patients with high disease activity (symptomatic index > 150) had a significantly lower PAF acetylhydrolase activity in plasma, as compared to patients in clinical remission (symptomatic index < 150; p < 0.02), and as compared to healthy subjects (p < 0.001). PAF acetylhydrolase activity in plasma increased within 4 months after bowel resection (P < 0.05). These findings indicate that the PAF acetylhydrolase activity is decreased in the ileal mucosa of patients with Crohn’s disease and that PAF acetylhydrolase activity in plasma is inversely related to disease activity in Crohn’s disease. The possibility that PAF acetylhydrolase is one factor of importance for protecting the intestinal mucosa against PAF-mediated inflammation is inferred.